Globus Medical (GMED)
(Delayed Data from NYSE)
$68.79 USD
+1.71 (2.55%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $68.83 +0.04 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Brokerage Reports
Globus Medical, Inc. [GMED]
Reports for Purchase
Showing records 1 - 20 ( 162 total )
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Provider: Zacks Investment Research
Analyst: Research Department
Company: Globus Medical, Inc.
Industry: Medical - Instruments
Company: Globus Medical, Inc.
Industry: Medical - Instruments
As Pre-Reported, but Still Early Stages On NUVA Merger
Provider: Roth Capital Partners, Inc.
Analyst: WHITE J